8-K Announcements
6Material company update
Mar 25, 2026·SEC
Material company update
Feb 25, 2026·SEC
Material company update
Feb 9, 2026·SEC
Anavex Life Sciences Corp.(AVXL)Earnings, Financials & Key Ratios
AVXL•NASDAQ
$3.34
$310M mkt cap·Price updated May 6, 2026
AboutAnavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$47M-1952.6%
- Net Income-$46M-7.8%
- EPS (Diluted)-0.54-3.8%
- ROE-43.11%-31.4%
AVXL Key Insights
Anavex Life Sciences Corp. (AVXL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 8 (bottom 8%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AVXL Price & Volume
Anavex Life Sciences Corp. (AVXL) stock price & volume — 10-year historical chart
Loading chart...
AVXL Growth Metrics
Anavex Life Sciences Corp. (AVXL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.08%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM15.67%
Return on Capital
10 Years-83.16%
5 Years-41.84%
3 Years-42.45%
Last Year-47.79%
AVXL Recent Earnings
Anavex Life Sciences Corp. (AVXL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)
Q1 2026Latest
Feb 9, 2026EPS
$0.06
Est $0.10
+40.0%
Revenue
—
Q4 2025
Nov 25, 2025EPS
$0.11
Est $0.13
+15.4%
Revenue
—
Q3 2025
Aug 12, 2025EPS
$0.16
Est $0.13
-23.1%
Revenue
—
Q2 2025
May 13, 2025EPS
$0.13
Est $0.16
+18.8%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 9, 2026 | $0.06vs $0.10+40.0% | — |
| Q4 2025 | Nov 25, 2025 | $0.11vs $0.13+15.4% | — |
| Q3 2025 | Aug 12, 2025 | $0.16vs $0.13-23.1% | — |
| Q2 2025 | May 13, 2025 | $0.13vs $0.16+18.8% | — |
Based on last 12 quarters of dataView full earnings history →
AVXL Peer Comparison
Anavex Life Sciences Corp. (AVXL) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SAVA | 94.44M | 1.96 | -3.76 | -95.77% | ||||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 ATNM | 38.68M | 1.24 | -0.98 | -100% | -384.43% | -151.67% | 0.05 | |
 BIIB | 28.15B | 190.68 | 21.59 | 1.39% | 13.92% | 7.55% | 0.38 | |
 LLY | 932.64B | 987.11 | 43.01 | 44.7% | 34.98% | 101.17% | 1.60 | |
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 | |
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 |
Compare AVXL vs Peers
Anavex Life Sciences Corp. (AVXL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AVXL Income Statement
Anavex Life Sciences Corp. (AVXL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | -685K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | 100% | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | 100% | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 15.54M | 19.18M | 29.11M | 30.94M | 41.95M | 50.99M | 55.76M | 52.88M | 51.41M | 44.6M |
| OpEx % of Revenue | - | - | -4249.2% | - | - | - | - | - | - | - |
| Selling, General & Admin | 5.01M | 6.14M | 6.85M | 5.86M | 9.15M | 13.07M | 12.04M | 11.04M | 13.82M | 12.8M |
| SG&A % of Revenue | - | - | -999.56% | - | - | - | - | - | - | - |
| Research & Development | 10.67M | 13.34M | 22.26M | 25.23M | 32.98M | 37.92M | 43.72M | 41.84M | 37.59M | 31.8M |
| R&D % of Revenue | - | - | -3249.63% | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | -151K | -186K | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -15.54M▲ 0% | -19.18M▼ 23.5% | -28.75M▼ 49.9% | -31.09M▼ 8.1% | -41.92M▼ 34.8% | -50.99M▼ 21.6% | -55.76M▼ 9.4% | -52.88M▲ 5.2% | -51.41M▲ 2.8% | -44.6M▲ 0% |
| Operating Margin % | - | - | 4197.37% | - | - | - | - | - | - | - |
| Operating Income Growth % | 0.32% | -23.46% | -49.87% | -8.13% | -34.85% | -21.62% | -9.36% | 5.16% | 2.78% | - |
| EBITDA | -15.54M | -1.68M | -2.11M | -30.63M | -4.47M | -54.31M | -58.47M | -2.29M | -47.02M | -30.09M |
| EBITDA Margin % | - | - | 308.18% | - | - | - | - | - | - | - |
| EBITDA Growth % | 0.32% | 89.17% | -25.51% | -1351.11% | 85.42% | -1116.05% | -7.67% | 96.08% | -1952.6% | 40.68% |
| D&A (Non-Cash Add-back) | 1.25K | 17.5M | 26.64M | 0 | 37.45M | -3.32M | -2.72M | 50.59M | 0 | 12.42M |
| EBIT | -15.42M | -18.98M | -28.53M | -30.63M | -42.19M | -50.94M | -53.04M | -45.29M | -47.02M | -41.28M |
| Net Interest Income | 0 | 224.15K | 56.15K | 179.97K | 26.26K | 0 | 5.55M | 7.32M | 4.68M | 4.36M |
| Interest Income | 88.1K | 255.09K | 207.28K | 179.97K | 26.26K | 946.99K | 6.52M | 7.32M | 4.68M | 4.36M |
| Interest Expense | 0 | 30.94K | 151.13K | 0 | 0 | 946.99K | 964K | 0 | 0 | 0 |
| Other Income/Expense | 2.28M | 2.1M | 3.08M | 4.83M | 4.28M | 3.37M | 8.26M | 9.88M | 5.03M | 4.67M |
| Pretax Income | -13.4M▲ 0% | -19.01M▼ 41.9% | -26.21M▼ 37.9% | -26.26M▼ 0.2% | -37.64M▼ 43.4% | -47.62M▼ 26.5% | -47.5M▲ 0.3% | -43M▲ 9.5% | -46.38M▼ 7.8% | -39.96M▲ 0% |
| Pretax Margin % | - | - | 3826.72% | - | - | - | - | - | - | - |
| Income Tax | 59.61K | 72.75K | 82.18K | 22.66K | 267.56K | 358.49K | 7K | 0 | 0 | -238K |
| Effective Tax Rate % | -0.44% | -0.38% | -0.31% | -0.09% | -0.71% | -0.75% | -0.01% | 0% | 0% | 0.6% |
| Net Income | -13.46M▲ 0% | -17.45M▼ 29.7% | -26.3M▼ 50.7% | -26.28M▲ 0.1% | -37.91M▼ 44.3% | -47.98M▼ 26.6% | -47.51M▲ 1.0% | -43M▲ 9.5% | -46.38M▼ 7.8% | -39.95M▲ 0% |
| Net Margin % | - | - | 3838.69% | - | - | - | - | - | - | - |
| Net Income Growth % | 8.67% | -29.67% | -50.66% | 0.06% | -44.25% | -26.56% | 0.99% | 9.48% | -7.85% | 14.08% |
| Net Income (Continuing) | -13.46M | -17.25M | -26.3M | -26.28M | -37.91M | -47.98M | -47.51M | -43M | -46.38M | -39.95M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.33▲ 0% | -0.39▼ 18.2% | -0.54▼ 38.5% | -0.45▲ 16.7% | -0.54▼ 20.0% | -0.62▼ 14.8% | -0.60▲ 3.2% | -0.52▲ 13.3% | -0.54▼ 3.8% | -0.45▲ 0% |
| EPS Growth % | 21.43% | -18.18% | -38.46% | 16.67% | -20% | -14.81% | 3.23% | 13.33% | -3.85% | 15.67% |
| EPS (Basic) | -0.33 | -0.39 | -0.54 | -0.45 | -0.54 | -0.62 | -0.60 | -0.52 | -0.54 | - |
| Diluted Shares Outstanding | 40.84M | 44.66M | 48.91M | 58.2M | 69.8M | 76.91M | 79.79M | 83.47M | 85.29M | 89.03M |
| Basic Shares Outstanding | 40.84M | 44.66M | 48.91M | 58.2M | 69.8M | 76.91M | 79.79M | 83.47M | 85.29M | 89.03M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AVXL Balance Sheet
Anavex Life Sciences Corp. (AVXL) balance sheet — assets, liabilities & shareholders' equity
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 27.79M | 24.32M | 25.33M | 34.54M | 161.62M | 152.7M | 154.39M | 135.57M | 103.81M | 132.99M |
| Cash & Short-Term Investments | 27.44M | 22.93M | 22.19M | 29.25M | 152.11M | 149.16M | 151.02M | 132.19M | 102.58M | 131.75M |
| Cash Only | 27.44M | 22.93M | 22.19M | 29.25M | 152.11M | 149.16M | 151.02M | 132.19M | 102.58M | 131.75M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 9.75K | 1.87M | 2.64M | 4.85M | 9.14M | 3.19M | 2.71M | 2.45M | 809K | 844K |
| Days Sales Outstanding | - | - | -1.41K | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | -2.64M | 0 | 16.36K | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 2.64M | 0 | -16.36K | 162 | 653K | 931K | 429K | 396K |
| Total Non-Current Assets | 52.4K | 52.4K | 0 | 5.29M | 16.36K | 3.55B | 3.36M | 0 | 0 | 0 |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 52.4K | 52.4K | 0 | 5.29M | 16.36K | 3.55B | 3.36M | 0 | 0 | 0 |
| Total Assets | 27.84M▲ 0% | 24.38M▼ 12.4% | 25.33M▲ 3.9% | 34.54M▲ 36.4% | 161.62M▲ 367.9% | 152.7M▼ 5.5% | 154.39M▲ 1.1% | 135.57M▼ 12.2% | 103.81M▼ 23.4% | 132.99M▲ 0% |
| Asset Turnover | - | - | -0.03x | - | - | - | - | - | - | 0.00x |
| Asset Growth % | 193.08% | -12.44% | 3.91% | 36.37% | 367.88% | -5.51% | 1.1% | -12.19% | -23.42% | -62.91% |
| Total Current Liabilities | 3.58M | 3.88M | 5.04M | 7.31M | 10.8M | 10.21M | 12.53M | 15.3M | 8.95M | 6.37M |
| Accounts Payable | 3.58M | 2.96M | 3.52M | 3.99M | 4.74M | 3.82M | 4.32M | 9.63M | 4.25M | 2.64M |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 443.83K | 443.83K | 0 | 842K | 805K | 3.24M |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | -47 | 6.85M | 1.53M | 1.56M | 1.7M |
| Current Ratio | 7.75x | 6.26x | 5.03x | 4.73x | 14.97x | 14.95x | 12.32x | 8.86x | 11.60x | 11.60x |
| Quick Ratio | 7.75x | 6.26x | 5.55x | 4.73x | 14.97x | 14.95x | 12.32x | 8.86x | 11.60x | 11.60x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.89M | 2.93M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.89M | 6.82M |
| Total Liabilities | 3.58M | 3.88M | 5.04M | 7.31M | 10.8M | 10.21M | 12.53M | 15.3M | 8.95M | 6.37M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -27.44M | -22.93M | -22.19M | -29.25M | -152.11M | -149.16M | -151.02M | -132.19M | -102.58M | -131.75M |
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 4.38x |
| Interest Coverage | - | -620.01x | -190.24x | - | - | -53.84x | -57.84x | - | - | - |
| Total Equity | 24.25M▲ 0% | 20.49M▼ 15.5% | 20.29M▼ 1.0% | 27.24M▲ 34.2% | 150.82M▲ 453.7% | 142.49M▼ 5.5% | 141.85M▼ 0.4% | 120.26M▼ 15.2% | 94.87M▼ 21.1% | 126.62M▲ 0% |
| Equity Growth % | 284.49% | -15.51% | -0.98% | 34.24% | 453.73% | -5.52% | -0.45% | -15.22% | -21.12% | -63.08% |
| Book Value per Share | 0.59 | 0.46 | 0.41 | 0.47 | 2.16 | 1.85 | 1.78 | 1.44 | 1.11 | 1.42 |
| Total Shareholders' Equity | 24.25M | 20.49M | 20.29M | 27.24M | 150.82M | 142.49M | 141.85M | 120.26M | 94.87M | 126.62M |
| Common Stock | 43.33K | 45.94K | 52.65K | 62.05K | 75.92K | 77.94K | 82K | 85K | 87K | 93K |
| Retained Earnings | -91.48M | -108.93M | -133.4M | -159.68M | -197.59M | -245.56M | -293.07M | -336.07M | -382.45M | -388.13M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AVXL Cash Flow Statement
Anavex Life Sciences Corp. (AVXL) cash flow — operating, investing & free cash flow history
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -9.02M | -12.58M | -18.53M | -21.29M | -30.38M | -24.24M | -27.79M | -30.81M | -39.04M | -39.04M |
| Operating CF Margin % | - | - | 2704.69% | - | - | - | - | - | - | - |
| Operating CF Growth % | 2.38% | -39.54% | -47.25% | -14.9% | -42.73% | 20.23% | -14.63% | -10.89% | -26.72% | -79.09% |
| Net Income | -13.46M | -17.45M | -26.29M | -26.28M | -37.91M | -47.98M | -47.51M | -43M | -46.38M | -39.95M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.14M | 5.52M | 6.43M | 4.88M | 8.23M | 18.38M | 16.37M | 9.44M | 11.55M | 10.6M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -75.2K | 5.61M | 35.38K | 0 | 403 | 242 | 845K | 0 | 0 | 0 |
| Working Capital Changes | 382.81K | -646K | 1.3M | 116.52K | -706.44K | 5.36M | 2.5M | 2.75M | -4.22M | -4.73M |
| Change in Receivables | 54.44K | -231.1K | -772.39K | -2.21M | -4.29M | 5.94M | 484K | 260K | 1.64M | 1.71M |
| Change in Inventory | 0 | 0 | 772.39K | 2.21M | 4.29M | -5.94M | 0 | 0 | 0 | 0 |
| Change in Payables | 554.71K | 38.23K | 683.8K | 465.72K | 750.73K | -915K | 497K | 5.3M | -5.38M | -1.93M |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 27.27M | 8.07M | 17.78M | 28.35M | 153.24M | 21.29M | 29.65M | 11.97M | 9.43M | 45.05M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 2.97M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -101.13K | -50K | -403.76K | 23.4K | 0 | 1.78M | 691K | -2.71M | -2.71M |
| Net Change in Cash | 18.25M▲ 0% | -4.51M▼ 124.7% | -745.01K▲ 83.5% | 7.06M▲ 1048.1% | 122.86M▲ 1639.4% | -2.95M▼ 102.4% | 1.87M▲ 163.3% | -18.84M▼ 1109.5% | -29.61M▼ 57.2% | 10.97M▲ 0% |
| Free Cash Flow | -9.02M▲ 0% | -12.58M▼ 39.5% | -18.53M▼ 47.2% | -21.29M▼ 14.9% | -30.38M▼ 42.7% | -24.24M▲ 20.2% | -27.79M▼ 14.6% | -30.81M▼ 10.9% | -39.04M▼ 26.7% | -34.08M▲ 0% |
| FCF Margin % | - | - | 2704.69% | - | - | - | - | - | - | - |
| FCF Growth % | 2.38% | -39.54% | -47.25% | -14.9% | -42.73% | 20.23% | -14.63% | -10.89% | -26.72% | 4.32% |
| FCF per Share | -0.22 | -0.28 | -0.38 | -0.37 | -0.44 | -0.32 | -0.35 | -0.37 | -0.46 | -0.46 |
| FCF Conversion (FCF/Net Income) | 0.67x | 0.72x | 0.70x | 0.81x | 0.80x | 0.51x | 0.58x | 0.72x | 0.84x | 0.85x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 22.66K | 140K | 327K | 136K | 300K | 125K | -2K |
AVXL Key Ratios
Anavex Life Sciences Corp. (AVXL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -88.08% | -78.01% | -128.96% | -110.59% | -42.58% | -32.71% | -33.41% | -32.81% | -43.11% | -31.55% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | - | 342.55% |
| Net Margin | - | - | 3838.69% | - | - | - | - | - | - | - |
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00x |
| Interest Coverage | - | -620.01x | -190.24x | - | - | -53.84x | -57.84x | - | - | - |
| FCF Conversion | 0.67x | 0.72x | 0.70x | 0.81x | 0.80x | 0.51x | 0.58x | 0.72x | 0.84x | 0.85x |
| Revenue Growth | - | - | - | 100% | - | - | - | - | - | - |
AVXL SEC Filings & Documents
Anavex Life Sciences Corp. (AVXL) SEC filings — annual & quarterly reports (10-K, 10-Q)
AVXL Frequently Asked Questions
Anavex Life Sciences Corp. (AVXL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Anavex Life Sciences Corp. (AVXL) grew revenue by 0.0% over the past year. Growth has been modest.
Anavex Life Sciences Corp. (AVXL) reported a net loss of $39.9M for fiscal year 2025.
Dividend & Returns
Anavex Life Sciences Corp. (AVXL) has a return on equity (ROE) of -43.1%. Negative ROE indicates the company is unprofitable.
Anavex Life Sciences Corp. (AVXL) had negative free cash flow of $34.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More AVXL
Anavex Life Sciences Corp. (AVXL) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates